Hepatitis C virus and blood transfusion: past and present risks (Q33809490)

29 July 2017

1 reference

title

Hepatitis C virus and blood transfusion: past and present risks (English)

1 reference

29 July 2017

1 reference

1 reference

van der Poel CL

1

1 reference

29 July 2017

1 January 1999

1 reference

29 July 2017

Journal of Hepatology

1 reference

29 July 2017

31 Suppl 1

1 reference

29 July 2017

101-106

1 reference

Blood transfusion and hepatitis: still a threat?

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

A review of recent events related to surrogate testing of blood to prevent non-A, non-B posttransfusion hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Low prevalence of antibody to hepatitis C virus in north east England

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Monetary blood donation incentives and the risk of transfusion-transmitted infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Look-back study of infectivity of anti-HCV ELISA-positive blood components

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

The Declining Risk of Post-Transfusion Hepatitis C Virus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Hepatitis C transmission in a hemodialysis unit: molecular evidence for spread of virus among patients not sharing equipment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

High prevalence of a rare hepatitis C virus in patients treated in the same hemodialysis unit: evidence for nosocomial transmission of HCV.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Nosocomial transmission of hepatitis C virus in haemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Hepatitis C virus in a hemodialysis unit: molecular evidence for nosocomial transmission

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Hepatitis C virus, antibodies, and infectivity. Paradox, pragmatism, and policy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

The progression of HCV-associated liver disease in a cohort of haemophilic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Hepatitis C virus genotypes and severity of chronic liver disease in haemophiliacs

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

The natural history of chronic hepatitis C in haemophiliacs

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Hepatitis C infection and viremia in Dutch hemophilia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Transmission of hepatitis C with pasteurised factor VIII.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Transmission of hepatitis C by pasteurised factor VIII

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Low risk of viral infection after administration of vapor-heated factor VIII concentrate. International Investigator Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Serological evidence that dry heating of clotting factor concentrates prevents transmission of non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Low risk for hepatitis C in hemophiliacs given a high-purity, pasteurized factor VIII concentrate. International Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Non-A, non-B hepatitis transmission by intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Molecular epidemiology of an outbreak of infection with hepatitis C virus in recipients of anti-D immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Outbreak of acute hepatitis C following the use of anti-hepatitis C virus--screened intravenous immunoglobulin therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Detection of antibodies to hepatitis C virus in U.S. blood donors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Risk factors in hepatitis C virus-infected blood donors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Screening blood donations for HCV

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Blood donors who are repeatedly reactive for hepatitis C virus on enzyme immunoassay and positive on recombinant immunoblot assay: evidence of failure to identify some risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Risk factors for hepatitis C virus antibody positivity in blood donors in a low-risk country

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Risk factors for hepatitis C virus infection. A case-control study of blood donors in the Trent Region (UK).

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Serum alanine aminotransferase of donors in relation to the risk of non-A,non-B hepatitis in recipients: the transfusion-transmitted viruses study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients. An analysis of the Transfusion-Transmitted Viruses Study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Antibody to hepatitis B core antigen as a paradoxical marker for non-A, non-B hepatitis agents in donated blood

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Relation between donor transaminase and recipient hepatitis non-A, non-B in Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Post-transfusion non-A, non-B hepatitis after cardiac surgery. Prospective analysis of donor blood anti-HBc antibody as a predictive indicator of the occurrence of non-A, non-B hepatitis in recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Post-transfusion hepatitis: impact of non-A, non-B hepatitis surrogate tests. Canadian Post-Transfusion Hepatitis Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Antibody to Hepatitis-C-Virus-Related Proteins in Sera from Alanine-Aminotransferase-Screened Blood Donors and Prospectively Studied Recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Infectivity of blood seropositive for hepatitis C virus antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Early antihepatitis C virus response with second-generation C200/C22 ELISA

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Post-transfusion hepatitis C in Finland

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Incidence of non-A, non-B hepatitis after screening blood donors for antibodies to hepatitis C virus and surrogate markers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Hepatitis C viremia in German blood donors: serum alanine aminotransferase is not a valid marker for screening

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Detection of antibody against antigen expressed by molecularly cloned hepatitis C virus cDNA: application to diagnosis and blood screening for posttransfusion hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Antibody to hepatitis C virus in post-transfusion hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Increased detection of hepatitis C virus infection in commercial plasma donors by a third-generation screening assay

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

Performance of three generations of anti-hepatitis C virus enzyme-linked immunosorbent assays in donors and patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980384-5

7 January 2021

10.1016/S0168-8278(99)80384-5

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10622570